Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
In this medfyle
Venetoclax in combination with gilteritinib led to high mCRc and FLT3 molecular response rates regardless of prior FLT3 inhibitor exposure in patients with FLT3-mutated R/R AML in this phase 1b study.
Expert commentary
About this Medfyle
This Medfyle is provided as a service to healthcare professionals. It has been created from content originally published in the Journal of Clinical Oncology® (JCO), an American Society of Clinical Oncology Journal, through an official agreement with Wolters Kluwer.
The summary content was prepared by Louise Gardner for Medfyle, reviewed & approved by Arnold Ganser, MD
Original article:
Daver N, Perl AE, Maly J, Levis M, Ritchie E, Litzow M, McCloskey J, Smith CC, Schiller G, Bradley T, Tiu RV, Naqvi K, Dail M, Brackman D, Siddani S, Wang J, Chyla B, Lee P, Altman JK. Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia. J Clin Oncol. 2022 Dec 10;40(35):4048-4059. doi: 10.1200/JCO.22.00602. Epub 2022 Jul 18. PMID: 35849791; PMCID: PMC9746764.
The authors of the original article had no part in the creation of the summary.
All Medfyle content, summaries, expert commentaries and slides are owned by GlobalPort (International) Limited. The original journal articles are an exclusive copyright of the American Society of Clinical Oncology.